1. Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Issue 11 (November 2020) Authors: Guo, Christina; Chénard-Poirier, Maxime; Roda, Desamparados; de Miguel, Maria; Harris, Samuel J; Candilejo, Irene Moreno; Sriskandarajah, Priya; Xu, Wen; Scaranti, Mariana; Constantinidou, Anastasia; King, Jenny; Parmar, Mona; Turner, Alison J; Carreira, Suzanne; Riisnaes, Ruth; Finneran, Laura; ... Journal: Lancet oncology Issue: Volume 21:Issue 11(2020) Page Start: 1478 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. Issue 6 (18th June 2022) Authors: Papadatos-Pastos, Dionysis; Yuan, Wei; Pal, Abhijit; Crespo, Mateus; Ferreira, Ana; Gurel, Bora; Prout, Toby; Ameratunga, Malaka; Chénard-Poirier, Maxime; Curcean, Andra; Bertan, Claudia; Baker, Chloe; Miranda, Susana; Masrour, Nahal; Chen, Wentin; Pereira, Rita; Figueiredo, Ines; Morilla, Ricard... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗